You are here

fitusiran

5 FDA decisions to watch in the first quarter of 2025

BioPharma Dive

Mon, 01/6/25 - 06:54 pm

Vertex Pharmaceuticals

non-opioid pain treatments

transthyretin amyloid cardiomyopathy

diazoxide choline

Prader Willi syndrome

Ash 2021 preview – small increases and big falls

EP Vantage

Mon, 11/8/21 - 10:50 am

Global Blood Therapeutics

IGM Biosciences

Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset

Fierce Biotech

Thu, 10/28/21 - 10:40 am

Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3

Fierce Biotech

Mon, 02/8/21 - 10:41 am

Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt

Endpoints

Thu, 12/10/20 - 07:20 pm

Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Pharmaforum

Mon, 11/9/20 - 10:59 am

Alnylam, Sanofi given the all-clear to resume fitusiran trials

BioPharma Dive

Sun, 12/17/17 - 10:24 am

clinical trials

Four months after patient death, FDA’s hold lifted on Alnylam’s fitusiran

Endpoints

Fri, 12/15/17 - 09:32 am

On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug

Xconomy

Thu, 09/7/17 - 05:46 pm

3 Biotech Stocks That Could Soar in September

Motley Fool

Sun, 08/27/17 - 06:26 pm

PTC Therapeutics

Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug

Endpoints

Fri, 07/7/17 - 10:22 am

clinical trials

Alnylam touts hemophilia drug's edge over Roche rival

BioPharma Dive

Fri, 12/2/16 - 10:48 am

Alnylam’s hemophilia drug appears to lower frequency of bleeding in early study

Bizjournals.com

Mon, 12/7/15 - 12:13 pm